iXensor

Name

iXensor

Legal name

iXensor Co., Ltd.

Website

https://ixensor.com

Company type

Public

Founded year

2012

Operating status

Operating

Headcount range

51–100 employees

Ownership category

akta.pro rank

Product category

Mobile In Vitro Diagnostics

NAICS

In-Vitro Diagnostic Substance Manufacturing (325413), Medical Equipment and Supplies Manufacturing (3391)

SIC

In Vitro & In Vivo Diagnostic Substances (2835), Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Cardiometabolic RPM & Chronic Disease Management (diabetes, hypertension, CHF, obesity) (HLALAFAA)

akta.pro secondary industry

Connected Therapeutics & Smart Drug Delivery Monitoring (HLACAFAL)

Keywords

• Smartphone diagnostic devices
• Point-of-care testing
• In vitro diagnostics
• Mobile health monitoring
• Biosensor technology

Headquarters

HQ city

Taipei

HQ country

Taiwan

HQ region

Asia

Offices2 records

Markets served

GTM type

B2B and B2C

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales, Infrastructure

Revenue model

1. Hardware and Consumable Sales: Sale of PixoTest Vision lipid testing devices and consumable test strips directly to consumers via own e-commerce store and regional distributors. Also includes sale of Eveline ovulation/fertility testing systems. Revenue is one-time per device plus recurring consumable revenue.
2. PixoTech® Platform Licensing: Licensing of the proprietary PixoTech technology platform to pharmaceutical companies (e.g., Rohto), medical device manufacturers (e.g., Innova Medical Group), and other IVD companies. Partners deploy PixoTech in their own products, creating a new growth engine for iXensor in the post-pandemic self-testing market.
3. CDMO Manufacturing Services: Contract Development and Manufacturing Organization services providing end-to-end solutions for POCT and at-home testing — from rapid test development, readers, apps, and cloud management to mass production with quality assurance. Targets lateral flow assay manufacturers, pharmaceutical partners, and MedTech innovators.
4. App Premium Subscription: PixoTest Vision app offers free core functionality with optional Premium upgrade for advanced AI health coaching, extended data analysis, and enhanced tracking features.
5. Strategic Investment Capital: iXensor received strategic investment from Rohto Pharmaceutical to expand its mobile health business globally and accelerate PixoTech platform licensing. This represents capital infusion rather than operational revenue.

Pricing tiers

Go-to-market motion3 records

Distribution channels6 records

Marketing channels8 records

Core offering

iXensor develops the PixoTech® platform that transforms ordinary smartphones into medical-grade in vitro diagnostic instruments by controlling smartphone camera sensors and multi-wavelength screen emissions to analyze colorimetric test results. The company sells branded at-home diagnostic products (PixoTest Vision for lipid testing, Eveline for ovulation/fertility) directly to consumers, and licenses its PixoTech platform technology to pharmaceutical and medtech partners (Rohto, Innova Medical Group) while providing contract development and manufacturing organization (CDMO) services.

Product overview

iXensor offers a platform-plus-modules architecture centered on the PixoTech technology platform, which transforms smartphones into medical-grade diagnostic devices. The core product family includes PixoTest-branded tests (Vision for lipids, Glucose for blood sugar, HbA1c for diabetes monitoring, COVID-19 antigen) and Eveline for women's fertility. These are complemented by software modules including the PixoHealth Vision App for device connectivity and data visualization, the Pixo App for AI-powered food analysis and holistic health management, and Eveline·Care for telehealth fertility consultations. Supporting infrastructure includes the PixoHealth Hub cloud platform for data storage and PixoTech XLab for remote co-development with partners. The company also offers CDMO services leveraging PixoTech platform licensing for third-party IVD manufacturers.

Differentiator

Problem solved

Functional benefit

Brands

• PixoTest Vision: Home lipid testing system with AI metabolic care - measures TC, TG, HDL, cLDL in 3 minutes with smartphone connectivity
• Eveline
• PixoHealth
• PixoTech

Products and services

• PixoTest Vision Home lipid testing device that measures TC, TG, HDL, and cLDL (calculated) in 3 minutes using smartphone-connected colorimetric analysis. Awarded 2025 Taiwan Excellence Award and TFDA-cleared. Includes Bluetooth connectivity for app sync and AI-powered metabolic tracking. Sold directly to consumers via shop.ixensor.com and regional distributors.
• PixoHealth Vision App
• Eveline Smart Fertility System Smart ovulation and fertility testing system combining hardware test strips with a smartphone app. Uses colorimetric analysis to track fertility indicators. Connected to Eveline·Care telehealth platform for licensed fertility consultation. US FDA-cleared and CE-Marked; sold across five continents.
• PixoTest COVID-19 Antigen Rapid Test COVID-19 antigen rapid test kit for detecting SARS-CoV-2, used with a smartphone camera for result interpretation. Received EU CE-IVD, Taiwan TFDA special manufacturing approval, and Australia TGA approval.
• PixoTest Blood Glucose Monitoring System World's first US FDA-approved smartphone camera-based blood glucose monitoring system. Transforms a smartphone into a medical-grade blood glucose meter using PixoTech technology. CE-marked for the European market.
• PixoTest HbA1c Monitoring System Point-of-care glycated hemoglobin (HbA1c) test system for diabetes management. Received TFDA approval (2019), Singapore HSA approval (2020), and US FDA 510(k) clearance (2019).
• Pixo App Comprehensive AI health management app with AI food photo analysis, calorie calculation, and nutrition suggestions. Integrates with PixoTest Vision for blood lipid tracking, blood glucose monitoring, and weight data. Includes 24/7 AI health coach chatbot.
• CDMO Services Contract Development and Manufacturing Organization services providing end-to-end solutions for point-of-care and at-home testing. Covers rapid test development, readers, apps, cloud management, and mass production with quality assurance. Targets lateral flow assay manufacturers, pharmaceutical partners, and MedTech innovators.

Quantifiable outcome

• 30,000+ users worldwide reached their health-management and family-planning goals
• +4 more outcomes

Named customers8 records

Segments4 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability9 records

Feature10 records

Partnerships

Ten partnerships are on record, tiered minor, flagship and core.

• Eu Yanjusheng (余仁生)minorStrategic or Co-development Partner · 24 March 2025iXensor partnered with international wellness brand Yu Ren Sheng (余仁生) to jointly target the personal health management market, combining iXensor's diagnostic technology with Yu Ren Sheng's wellness products and brand.
• TMSC (Vietnam) — 德美生越南智慧科技公司minorChannel Partner/ Reseller/ Distributor · 25 February 2025iXensor deepened its partnership with Vietnamese company TMSC (德美生越南智慧科技公司) to pursue chronic disease management market opportunities in Vietnam, with TMSC serving as a regional channel partner for Southeast Asia.
• Barrett Comiskey (E Ink co-inventor)minorStrategic or Co-development Partner · 25 September 2023iXensor partnered with Barrett Comiskey, co-inventor of e-paper technology, to focus on the billion-dollar US women's health market, potentially leveraging complementary display and sensing technologies.
• Martell (United States)minorStrategic or Co-development Partner · 25 September 2023iXensor signed a Letter of Intent with US laboratory testing company Martell for a breast cancer detection collaboration, expanding into oncology diagnostics.
• Innova Medical GroupflagshipStrategic or Co-development Partner · 14 November 2022Partnership announced at MEDICA 2022 in Düsseldorf. Innova Medical Group, a global scale-up platform for rapid screening and diagnosis with 2 billion+ rapid test kits delivered since 2020, launched the PHRONESIA Smart Ovulation Test — the first 'Powered by iXensor Technology' product in its PHRONESIA self-tests portfolio. The product integrates hardware, app, and cloud solution manufactured cost-effectively by iXensor.
• Johnson & Johnson Innovation — JLABS @ ShanghaicoreStrategic or Co-development Partner · 14 November 2022iXensor became a resident of Johnson & Johnson Innovation – JLABS @ Shanghai effective December 1, 2020. The residency aims to accelerate PixoTech platform development and smartphone-based testing applications in infectious diseases, cardiovascular, and neuroscience areas, leveraging JLABS' global network and resources.
• Plug & Play / Startup CreasphereminorStrategic or Co-development Partner · 14 November 2022iXensor was selected into the Roche-backed Plug & Play's Startup Creasphere accelerator program, which focuses on digital health startups. This supported iXensor's development and global visibility in the healthcare innovation ecosystem.
• Ilara Health (Africa)minorStrategic or Co-development Partner · 14 November 2022Ilara Health partners with iXensor to bridge the diagnostics divide in Africa by connecting healthcare facilities to disruptive diagnostic devices powered by PixoTech technology.
• Rohto Pharmaceutical Co., Ltd. (樂敦製藥)coreStrategic or Co-development Partner · 27 April 2022In addition to the strategic investment, iXensor and Rohto entered a separate technology licensing and joint development agreement. Rohto received a technical license for smartphone-based diagnostic devices and apps from iXensor to develop and sell innovative self-testing products in Japan. This licensing shift is positioned as iXensor's new growth engine in the post-pandemic era.
• Merck — CURAFA Points of Care (Kenya)coreStrategic or Co-development Partner · 1 August 2019iXensor was selected into the Merck Accelerator program in 2019 (from 565 applications across 68 countries). The partnership led to deployment of PixoTest POCT Systems at CURAFA healthcare facilities in Kenya, a pilot project providing instant clinical tests for diabetes (HbA1c) and cardiovascular diseases (lipid panel) at decentralized community pharmacies. The pilot received excellent user and pharmacy response.

Scale indicators10 records

Recent moves7 records

Expansion highlights6 records

Broad incumbents

• Roche Diagnostics: Roche is the largest global IVD player and partners with digital health accelerators (e.g., Plug & Play's Startup Creasphere where iXensor participated) — broader incumbent with overlapping diagnostic categories.
• Bio-Rad Laboratories: Bio-Rad is an established diagnostics and life science research company with overlapping IVD reagents and clinical chemistry; iXensor channels tests on a smaller scale through similar laboratory and clinical workflows.
• QuidelOrtho: QuidelOrtho (Sofia, QuickVue, Triage) is a US-headquartered rapid diagnostics incumbent with overlapping lateral-flow and consumer IVD adjacencies to iXensor's connected test platform.
• Abbott Diagnostics: Abbott is a global IVD incumbent with overlapping point-of-care and consumer diagnostics offerings (i-STAT, Binax, FreeStyle Libre) — adjacent to iXensor's lipid, glucose, and HbA1c franchises.

Direct peers

• AliveCor: AliveCor's KardiaMobile uses smartphone connectivity to deliver FDA-cleared cardiac diagnostics — a clear peer in smartphone-based, connected, consumer-facing regulated medical devices.
• Cue Health: Cue Health developed the Cue Reader, a connected molecular diagnostic device that pairs with a smartphone app to deliver test results — a directly comparable business model to iXensor's smartphone-based diagnostics.
• Withings: Withings builds connected consumer health devices (e.g., Body Scan, ScanWatch) that integrate with a smartphone app — comparable to iXensor's hardware-plus-app-plus-cloud consumer health platform.
• Healthy.io: Healthy.io turns smartphone cameras into clinical-grade urinalysis (DIP) and kidney diagnostics, overlapping directly with iXensor's smartphone-camera-driven IVD platform and B2C/B2B hybrid GTM.

Emerging players

• Scanwell Health: Scanwell Health produces smartphone-based at-home diagnostics (e.g., UTI, kidney disease), closely mirroring iXensor's smartphone-camera-based consumer IVD approach on a smaller, niche-focused scale.

Regional players

• EKF Diagnostics: EKF Diagnostics focuses on point-of-care diagnostics (HbA1c, hemoglobin) in European and emerging markets — directly comparable product categories and overlapping geographies where iXensor operates (Italy, DM pharmacies, Kenya).

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks7 records

Key highlights7 records

Customer concentration

• Xx.com/ixensor
• YouTubeyoutube.com/channel/UCCd_kxV1kmlFuuXyRBadOqQ
• Facebookfacebook.com/iXensor
• LinkedInlinkedin.com/company/ixensor

Compliance10 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Subsidiaries1 record

Funding overview

Funding rounds5 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about iXensor